Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...
On February 2, Wave Life Sciences Ltd. (NASDAQ:WVE) said it regained full rights to WVE-006, a potential treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results